Company Description
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.
It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial.
The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 5, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Jeremy Levin |
Contact Details
Address: 441 Ninth Avenue, 14th Floor New York, New York 10001 United States | |
| Phone | 646 661 7661 |
| Website | ovidrx.com |
Stock Details
| Ticker Symbol | OVID |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636651 |
| CUSIP Number | 690469101 |
| ISIN Number | US6904691010 |
| Employer ID | 46-5270895 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Chief Executive Officer and Chairman |
| Jeffrey A. Rona | Chief Business and Financial Officer |
| Meg Alexander | President and Chief Operating Officer |
| Dr. Dirk Haasner | Senior Vice President of Global Manufacturing and CMC QA |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Zhong Zhong Ph.D. | Chief Scientific Officer |
| Tom Parry | Vice President of Research and Early Development |
| Garret Bonney | Investor Relations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |